News

Cancer-hunting antibodies coupled with a natural compound found in soil microbes proved a powerful combination against an aggressive type of blood cancer, according to a new study from scientists at ...
Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...
For the first time, scientists have systematically studied the genetic effects of chemotherapy on healthy tissues.
A new treatment option, Datroway (datopotamab deruxtecan or Dato-DXd), is now available for people with non-small cell lung ...
Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood ...
A team of researchers led by NYU Tandon School of Engineering's Weiqiang Chen has developed a miniature device that could ...
Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...
A potential treatment for glioblastoma crafted by scientists at The Wertheim UF Scripps Institute renders the deadly brain ...
Read Ino’s inspiring cancer journey and discover how cutting-edge treatments and pediatric clinical trials are providing hope ...
It is also studying the drug as a first-line treatment, which could add to that revenue forecast, Miels said. Meanwhile, Merck and Daiichi Sankyo face a new hurdle for a drug they are developing.
As a first-line treatment, Trodelvy combined with Keytruda lowered the risk of disease progression by 35% in patients with an aggressive type of breast cancer in a late-stage trial.